Literature DB >> 26560493

Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.

Hakan Gunes, Tarik Kivrak1.   

Abstract

Eltrombopag is a non-peptide thrombopoietin receptor agonist. Eltrombopag has originally been developed for conditions where therapy for thrombocytopenia is needed. Secondary to eltrombopag have been reported thrombotic events, chest pain, acute renal failure, neutropenia, ascites, retinal exudates, antiphospholipid syndrome. In this case, we present a 53 year-old patient who had diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) for 30 years with splenectomy. He's still having low thrombocyte counts despite the classical ITP therapy. He was treated with eltrombopag for the last 2 months and had inferior myocardial infarction despite that having no additional risk factors for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26560493     DOI: 10.2174/1574886311207040255

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  4 in total

1.  Is the increase in eltrombopag dose cause of myocardial infarction?

Authors:  Edip Can Özgünoğlu; Nermin Bayar; Şakir Arslan; Muhammed Rıdvan Ersoysal; Rauf Avcı
Journal:  Anatol J Cardiol       Date:  2021-07       Impact factor: 1.596

2.  Recurrent Coronary Thrombus in a Patient with Chronic Immune Thrombocytopenia with Treatment Using Eltrombopag.

Authors:  Terumori Satoh; Masao Saotome; Kenichiro Suwa; Hayato Ohtani; Yasuyuki Nagata; Takaaki Ono; Yuichiro Maekawa
Journal:  Case Rep Cardiol       Date:  2019-03-26

3.  A sticky situation: myocardial infarction in a young woman with immune thrombocytopenia on eltrombopag and a history of mediastinal radiation.

Authors:  Jennifer Teichman; Ahmed Taher; Abdulaziz Hashi; Akshay Bagai; Michelle Sholzberg
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

4.  Computational models for the prediction of adverse cardiovascular drug reactions.

Authors:  Salma Jamal; Waseem Ali; Priya Nagpal; Sonam Grover; Abhinav Grover
Journal:  J Transl Med       Date:  2019-05-22       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.